Corient Private Wealth LLC Purchases 4,015 Shares of Masimo Corporation $MASI

Corient Private Wealth LLC raised its position in Masimo Corporation (NASDAQ:MASI) by 1.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 340,230 shares of the medical equipment provider’s stock after acquiring an additional 4,015 shares during the quarter. Corient Private Wealth LLC’s holdings in Masimo were worth $44,250,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of MASI. Vanguard Group Inc. increased its stake in shares of Masimo by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 4,810,011 shares of the medical equipment provider’s stock worth $709,717,000 after purchasing an additional 171,876 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Masimo by 1.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 2,663,875 shares of the medical equipment provider’s stock valued at $346,464,000 after purchasing an additional 43,915 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Masimo by 9.6% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,330,158 shares of the medical equipment provider’s stock worth $303,061,000 after purchasing an additional 203,395 shares during the period. Naya Capital Management UK Ltd. bought a new position in Masimo during the fourth quarter worth about $202,984,000. Finally, Westfield Capital Management Co. LP increased its position in Masimo by 7.2% during the fourth quarter. Westfield Capital Management Co. LP now owns 1,522,049 shares of the medical equipment provider’s stock worth $197,958,000 after buying an additional 102,799 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Raymond James Financial lowered Masimo from an “outperform” rating to a “market perform” rating in a research note on Friday, March 27th. Wells Fargo & Company upgraded Masimo to a “hold” rating in a research note on Wednesday, March 18th. Finally, Weiss Ratings upgraded Masimo from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Nine investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $180.40.

Masimo Price Performance

Shares of MASI opened at $179.95 on Monday. The company’s 50-day moving average is $178.84 and its 200-day moving average is $161.91. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.68 and a quick ratio of 1.45. The firm has a market capitalization of $9.42 billion, a PE ratio of -17.07, a PEG ratio of 1.82 and a beta of 1.11. Masimo Corporation has a fifty-two week low of $125.94 and a fifty-two week high of $179.99.

Masimo Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.